Preoperative PSA is still predictive of cancer volume and grade in late PSA era.

[1]  James A Hanley,et al.  13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. , 2007, The Journal of urology.

[2]  P. Troncoso,et al.  The relationship between serum prostate specific antigen level and tumor volume persists in the current era. , 2007, The Journal of urology.

[3]  W. Catalona,et al.  Prostate specific antigen density correlates with features of prostate cancer aggressiveness. , 2007, The Journal of urology.

[4]  P. Carroll,et al.  Recommendations for defining and treating high risk localized prostate cancer. , 2006, The Journal of urology.

[5]  A. Renshaw,et al.  Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. , 2006, The Journal of urology.

[6]  E W Steyerberg,et al.  Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. , 2006, The Journal of urology.

[7]  A. Partin,et al.  The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy. , 2005, The Journal of urology.

[8]  Alan W Partin,et al.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. , 2005, JAMA.

[9]  Rosalie Nolley,et al.  The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? , 2004, The Journal of urology.

[10]  William J Catalona,et al.  More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects. , 2004, Urology.

[11]  A. Renshaw,et al.  Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. , 2002, Urology.

[12]  J. Richie,et al.  Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. , 2000, Urology.

[13]  H. Levin,et al.  Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[15]  T. Stamey,et al.  Biological determinants of cancer progression in men with prostate cancer. , 1999, JAMA.

[16]  A. Renshaw,et al.  Estimation of tumor volume in radical prostatectomy specimens in routine clinical practice. , 1997, American journal of clinical pathology.

[17]  H. Levin,et al.  Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. , 1997, International journal of radiation oncology, biology, physics.

[18]  D. Chan,et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[19]  A W Partin,et al.  Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. , 1993, The Journal of urology.

[20]  T. Stamey,et al.  PATTERNS OF PROGRESSION IN PROSTATE CANCER , 1986, The Lancet.